Anticoagulant/Antiaggregant Use and Postoperative Bleeding Risk in Patients With Bladder Tumor and Benign Prostatic Hyperplasia

Study Overview
=================
Brief Summary
-----------------
Patients who were using anticoagulant or antiaggregant medications for any reason and underwent transurethral resection of bladder tumor (TUR-BT) or transurethral resection of the prostate (TURP) or open prostatectomy (OP) due to BPH will be compared with those who were not using anticoagulant or antiplatelet medication. The rates of postoperative clot retention, presence of hematuria, reoperation due to hematuria, blood transfusion and re-admissions due to hematuria in the first postoperative month will be compared.

Official Title
-----------------
Investigation of the Effects of Anticoagulant/Antiaggregant Use on Postoperative Bleeding Risk in Patients Operated for Bladder Tumor and Benign Prostatic Hyperplasia

Conditions
-----------------
Hematuria, Retention, Urinary, Operative Bleeding, Blood Transfusion Complication

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing complete endoscopic transurethral tumor resection (TUR-BT) for bladder cancer Patients undergoing TURP due to benign prostatic hyperplasia Patients undergoing open prostatectomy due to benign prostatic hyperplasia Exclusion Criteria: Patients who underwent incomplete transurethral tumor resection for bladder cancer Patient who underwent TUR biopsy for restaging with no obvious macroscopic tumoral lesion Patients who underwent cystectomy for bladder cancer
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TURP patients using anticoagulant/antiaggregant medication<br>Patients who used anticoagulant/antiaggregant medication for any reason (eg: coronary artery disease, atrial fibrillation, cerebrovascular disease) before surgery and underwent endoscopic prostatectomy (TURP). | |
| TURP patients not using anticoagulant/antiaggregant medication<br>Patients with no history of anticoagulant/antiaggregant medication and underwent endoscopic prostatectomy (TURP). | |
| TUR-BT patients using anticoagulant/antiaggregant medication<br>Patients who used anticoagulant/antiaggregant medication for any reason (eg: coronary artery disease, atrial fibrillation, cerebrovascular disease) before surgery and underwent endoscopic bladder tumor resection (TUR-BT). | |
| TUR-BT patients not using anticoagulant/antiaggregant medication<br>Patients with no history of anticoagulant/antiaggregant medication and underwent endoscopic bladder tumor resection (TUR-BT). | |
| Open prostatectomy patients using anticoagulant/antiaggregant medication<br>Patients who used anticoagulant/antiaggregant medication for any reason (eg: coronary artery disease, atrial fibrillation, cerebrovascular disease) before surgery and underwent open prostatectomy (OP). | |
| Open prostatectomy patients not using anticoagulant/antiaggregant medication<br>Patients with no history of anticoagulant/antiaggregant medication and underwent open prostatectomy (OP). | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Episode of clot retention | Presence of clot retention due to hematuria after the operation which requires manuel irrigation | Immediately after the surgery up to 1 month | 
| Requirement of blood transfusion | Gross hematuria requiring blood transfusion | Immediately after the surgery up to 1 month | 
| Re-operation rates | Re-operation requirement for hematuria | Immediately after the surgery up to 1 month | 
| Duration of hospitalization | Duration of hospitalization | Immediately after the surgery up to discharge | 
| Rate of re-admission | Rate of re-admission due to hematuria | From discharge up to one month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative hematocrit/hemoglobin levels | Change in the Postoperative hematocrit/hemoglobin levels compared to the preoperative values. | Immediately after the surgery up to discharge | 
| Amount of irrigation volume | Amount of postoperative continuous bladder irrigation volume | Immediately after the surgery up to discharge | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bladder cancer, benign prostatic hyperplasia, transurethral resection, hematuria